Growing drug delivery CDMO Kindeva expands UK operations
US-headquartered company Kindeva seals deal for an R&D facility at Loughborough’s life sciences hub
Global contract development and manufacturing organisation (CDMO) Kindeva Drug Delivery has expanded its UK operations by securing a deal for an R&D facility and 20,000 sq. ft of office space at its Charnwood Campus site in Loughborough.
Formerly 3M Drug Delivery Systems, Kindeva specialises in drug delivery and combination products for its pharmaceutical and biotechnology customers and currently employs over 500 staff in the UK across its two sites at Loughborough and Clitheroe.
Charnwood Campus is now home to four blue-chip organisations including Almac, 3M, Kindeva, and global diagnostics company PerkinElmer. It is also the first and only Life Sciences Opportunity Zone in the UK and part of the Loughborough and Leicester Science and Innovation Enterprise Zone.
“As a growing CDMO and life sciences company, Kindeva thrives on our base of well-trained, highly-qualified leaders in scientific R&D,” said Aaron Mann, CEO of Kindeva Drug Delivery.
“The Charnwood campus provides a state-of-the-art laboratory design to support our industry-leading talent. Importantly, the proximity to general management offices promotes cross-functional collaboration between our R&D team and other areas of the business, enabling consistent feedback of customer needs and insights into our R&D activities.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.